Hope Biosciences Research Foundation
27
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.1%
3 terminated/withdrawn out of 27 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
HB-adMSCs for the Treatment of Crohn's Disease
Role: lead
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
Role: lead
Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury
Role: lead
Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
Role: lead
HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis
Role: lead
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
Role: lead
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
Role: lead
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Role: lead
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy
Role: lead
Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
Role: lead
Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.
Role: lead
Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.
Role: lead
Individual Patient Expanded Access IND to Treat Polyneuropathy
Role: lead
Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease
Role: lead
"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"
Role: lead
Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.
Role: lead
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease
Role: collaborator
Individual Patient Expanded Access IND for the Treatment of Stroke
Role: lead
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury
Role: lead
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome
Role: lead